Loss of p300 accelerates MDS-associated leukemogenesis

G. Cheng, F. Liu, T. Asai, F. Lai, N. Man, H. Xu, S. Chen, S. Greenblatt, P. J. Hamard, K. Ando, X. Chen, L. Wang, C. Martinez, M. Tadi, L. Wang, M. Xu, F. C. Yang, R. Shiekhattar, S. D. Nimer

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


The role that changes in DNA methylation and histone modifications have in human malignancies is poorly understood. p300 and CREB-binding protein (CBP), two distinct but highly homologous lysine acetyltransferases, are mutated in several cancers, suggesting their role as tumor suppressors. In the current study, we found that deletion of p300, but not CBP, markedly accelerated the leukemogenesis ofNup98-HoxD13 (NHD13) transgenic mice, an animal model that phenotypically copies human myelodysplastic syndrome (MDS). p300 deletion restored the ability of NHD13 expressing hematopoietic stem and progenitor cells (HSPCs) to self-renew in vitro, and to expand in vivo, with an increase in stem cell symmetric self-renewal divisions and a decrease in apoptosis. Furthermore, loss of p300, but not CBP, promoted cytokine signaling, including enhanced activation of the MAPK and JAK/STAT pathways in the HSPC compartment. Altogether, our data indicate that p300 has a pivotal role in blocking the transformation of MDS to acute myeloid leukemia, a role distinct from that of CBP.

Original languageEnglish (US)
Pages (from-to)1382-1390
Number of pages9
Issue number6
StatePublished - Jun 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Loss of p300 accelerates MDS-associated leukemogenesis'. Together they form a unique fingerprint.

Cite this